Results 61 to 70 of about 750,934 (136)

Strategies to target PD-1/PD-L1 in the tumor microenvironment. [PDF]

Cell Oncol (Dordr)
Kui Y, Tong F, Zhang R, Dong X, Wang J.
europepmc   +1 more source

Discovery and characterization of two anti-PD-1 antibodies with a unique binding mechanism to human PD-1. [PDF]

MAbs
Castellano KMG, Luna AM, de Jesús Carballo Uicab G, Villedas FDR, Rodríguez LJE, Leyva SKV, Luna SDR, González EG, Escalona MMP, Holland B, Cristina PD, Santiago CR, Saldaña HAB, Tapia SMP, Almagro JC.   +14 more
europepmc   +1 more source

The role of PD‑1/PD‑L1 axis in liver diseases. [PDF]

Clin Exp Med
Zeng Z, Chen S, Niu Q, Dong H, Yao Y, Wang K, Gong X, Li H.   +7 more
europepmc   +1 more source

Circulating PD-1⁺ effector memory T cells predict anti-PD-1 efficacy in advanced gastric cancer. [PDF]

Front Immunol
Wang K, Shao J, Xin K, Zhang L, Liu B, Chen W, Liu Q.   +6 more
europepmc   +1 more source

Anti-PD-1-induced bullous pemphigoid in a renal transplant recipient. [PDF]

SAGE Open Med Case Rep
Barnawi G, Kpata AJ, Aldibane R, Kashkari S, Lazarowitz R, Khanna M.   +5 more
europepmc   +1 more source

Modulating <i>Bacteroides</i> to boost anti-PD-1 immunotherapy in HCC. [PDF]

J Immunother Cancer
Qi X, Yang M, Liu X, Ma L, Kaifi JT, Ericsson AC, Kimchi ET, Staveley-O'Carroll KF, Li G.   +8 more
europepmc   +1 more source

HER2 (EGFR2; ErbB2; neu); PD-1 receptor (PDCD1; PD-1; CD279) [PDF]

Science-Business eXchange, 2013
openaire   +1 more source

Myasthenia-Like Presentations Following PD-1 Inhibitors: CD8+ Myositis, Myasthenia, or Both? [PDF]

Cureus
Ucem S, Yunisova G, Bulus E, Lacin S, Oflazer P.   +4 more
europepmc   +1 more source

Molecular dynamics insights into the redox effects on PD-1/PD-L1 and PD-1/PD-L2 interactions. [PDF]

Sci Rep
Mashalov R, Toshpulatova Z, Chen Z, Razzokov J.   +3 more
europepmc   +1 more source

PD-1 Blockade–induced Inflammatory Arthritis [PDF]

Radiology, 2018
Tomomi, Nobashi, Erik, Mittra
openaire   +2 more sources